EP0341104A3
Substituted flavonoid compounds, their salts, their manufacture and medicines containing these materials
Abstract
Substituted flavonoid compounds of the formula (I): are disclosed. These compounds possess anticancer activity, in particular antipancreatic cancer activity, together with immunomodulatory activity.
Term
Term ended
Projected expiry passed 6 April 2009, 17.5 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
1 sheet
Sheet 1
Every citation, both ways
| Document | Relation | Office | Category | Cited during |
|---|---|---|---|---|
| EP0080934A1 | Cites | European Patent Office (EPO) | A | Search report |
| EP0123113A2 | Cites | European Patent Office (EPO) | A | Search report |
| EP0283761A1 | Cites | European Patent Office (EPO) | AP | Search report |
| DE1270567B | Cites | Germany | A | Search report |
| DE3517950A1 | Cites | Germany | A | Search report |
37 members in 21 offices
Priority claims5
| Document | Office | Kind | Date |
|---|---|---|---|
| 178315 | United States of America | – | |
| 17831588 | United States of America | A | |
| 17831588 | United States of America | A | |
| 178315 | – | – | – |
| US19880178315 | – | – | – |
Members37
| Document | Office | Kind | |
|---|---|---|---|
| NO891415D0 | Norway | D0 | |
| DK166789D0 | Denmark | D0 | |
| IE891087L | Ireland | L | |
| DK166789A | Denmark | A | |
| NO891415L | Norway | L | |
| AU3250589A | Australia | A | |
| HUT49600A | Hungary | A | |
| EP0341104A2 | European Patent Office (EPO) | A2 | |
| PT90214A | Portugal | A | |
| EP0341104A3This record | European Patent Office (EPO) | A3 | |
| IL89840A0 | Israel | A0 | |
| IL89840D0 | Israel | D0 | |
| MA21528A1 | Morocco | A1 | |
| JPH026473A | Japan | A | |
| ZA892523B | South Africa | B | |
| OA09036A | African Intellectual Property Organization (OAPI) | A | |
| YU69289A | Yugoslavia, later Serbia and Montenegro (until 2006) | A | |
| NZ228625A | New Zealand | A | |
| US5116954A | United States of America | A | |
| SU1739846A3 | Soviet Union (until 1991) | A3 | |
| IN170909B | India | B | |
| AU630345B2 | Australia | B2 | |
| HU206701B | Hungary | B | |
| NO172344B | Norway | B | |
| NO172344C | Norway | C | |
| CA1325205C | Canada | C | |
| EP0341104B1 | European Patent Office (EPO) | B1 | |
| AT99302T | Austria | T | |
| ATE99302T1 | Austria | T1 | |
| DE68911742D1 | Germany | D1 | |
| DE68911742T2 | Germany | T2 | |
| PT90214B | Portugal | B | |
| ES2060799T3 | Spain | T3 | |
| YU47308B | Yugoslavia, later Serbia and Montenegro (until 2006) | B | |
| IE62858B1 | Ireland | B1 | |
| USH1427H | United States of America | H | |
| IL89840A | Israel | A |
53 legal events, as 5 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Notification of lapseLapsedST | ST | FR | |
| Se: european patent has lapsedLapsedEUG | EUG | EP | |
| Nl: lapsed or anulled due to non-payment of the annual feeLapsedNLV4 | NLV4 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| Annulment or lapse due to non-payment of feesLapsed3011181MM2A | MM2A | GR | |
| Gb: european patent ceased through non-payment of renewal feeCeasedGBPC | GBPC | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Be: lapsedLapsedBERE | BERE | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Se: european patent in force in swedenEAL | EAL | EP | |
| No opposition filedOpposition26N | 26N | EP | |
| Definitive protectionFG2A | FG2A | ES | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Lu: last paid annual feeEPTA | EPTA | EP | |
| Validation in greece3011181FG4A | FG4A | GR | |
| Fr: translation filedET | ET | EP | |
| Corresponds to:REF | REF | EP | |
| Designated contracting statesAK | AK | EP | |
| Corresponds to:REF | REF | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| It: translation for a ep patent filedITF | ITF | EP | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Party data changed (applicant data changed or rights of an application transferred)RAP1 | RAP1 | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Designated contracting statesAK | AK | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 0341104
- Publication, DOCDB
- 0341104
- Publication, EPODOC
- EP0341104
- Application
- 89400953
- Application, DOCDB
- 89400953
- Application, EPODOC
- EP19890400953
Titles3
- German
- Substituierte flavonoide Verbindungen, ihre Salze, ihre Herstellung und die enthaltende Arnzeizusammensetzungen
- English
- Substituted flavonoid compounds, their salts, their manufacture and medicines containing these materials
- French
- Composés flavonoides substitués, leurs sels, procédé de leur préparation et compositions pharmaceutiques les contenant
Classification
- CPC, 18
- C07D215/233
- A61P7/02
- C07D311/22
- A61P35/00
- C07D311/30
- A61P37/00
- C07D311/92
- C07D335/06
- C07D345/00
- C07D405/04
- C07D405/06
- C07D405/12
- C07D407/04
- C07D417/04
- C07D417/10
- C07D471/04
- C07D513/04
- C07F9/65522
- IPC, 35
- A61K31 35
- A61K31 352
- A61K31 38
- A61K31 382
- A61K31 415
- A61K31 425
- A61K31 435
- A61K31 44
- A61K31 443
- A61K31 47
- A61K31 495
- A61P7 02
- A61P35 00
- A61P37 00
- C07D215 22
- C07D215 233
- C07D311 22
- C07D311 24
- C07D311 26
- C07D311 30
- C07D311 78
- C07D311 92
- C07D335 06
- C07D345 00
- C07D405 00
- C07D405 04
- C07D405 06
- C07D405 12
- C07D407 04
- C07D417 00
- C07D417 04
- C07D417 10
- C07D471 04
- C07D513 04
- C07F9 655
Designated states13
- Contracting states, 13
- Austria
- Belgium
- Switzerland
- Germany
- Spain
- France
- United Kingdom
- Greece
- Italy
- Liechtenstein
- Luxembourg
- Netherlands (Kingdom of the)
- Sweden